Vyepti Dosage/Direction for Use

As for other infusion treatments, VYEPTI treatment should be initiated and supervised by a healthcare professional.
Posology: The recommended dose is 100 mg administered by intravenous infusion every 12 weeks. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 12 weeks (see Pharmacology: Pharmacodynamics under Actions).
Special Populations: Elderly (aged 65 years and over): Although patients aged up to 75 years were included in one study, the clinical study program of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No dose adjustment is required in elderly patients as the pharmacokinetics of Vyepti are not affected by age (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment/hepatic impairment: No dose adjustment is required in patients with renal impairment or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of eptinezumab in children below the age of 18 years has not yet been established. Currently no data are available.
Method of administration: Eptinezumab is for intravenous infusion only after dilution.
For instructions on dilution of the medicinal product prior to administration, see Special precautions for disposal and other handling under Cautions for Usage.